Evoke Pharma Jumps 20% After Clinical Trial-Phase 2b Assessing EVK-001 Print
By William Kent   
Wednesday, 24 June 2015 15:00

Speciality pharmaceutical firm Evoke Pharma Inc (NASDAQ:EVOK) has confirmed that the earlier revealed results from the Phase 2b clinical trial assessing EVK-001, the patented formulation of metoclopramide for relief of symptoms related to acute as well as recurrent diabetic gastroparesis in women, has been given in the July issue of the leading peer reviewed journal, Clinical Gastroenterology and Hepatogology.

Henry P. Parkman, M.D., Director of the GI Motility Laboratory at the Temple University School of Medicine, opined that the phase 2 shows EVK-001's potential as effective treatment which is well-tolerated by women who suffer from diabetic gastroparesis.

  

He added that over 80% of all diagnosed diabetic gastroparesis patients are women. Parkman further added that the data from controlled clinical trials shows that Evoke's novel intranasal spray is ideal administration for the patients having just some treatment options.

  

The MD further feels that unlike oral formulations which can have erratic absorption from GI tract, EVK-001's absorption is not affected by delayed gastric symptoms like vomiting.

  

The randomized Phase 2b study had 285 patients (71% female) with type 1 or type 2 diabetes as well as earlier diagnosis of gastroparesis.

  

In females, gastroparesis symptom demonstrated significant improvement when provided with EVK-001 vis-a-vis placebo. In males, EVK-001 did not show improvement vis-a-vis placebo.

   

Marilyn Carlson, D.M.D., M.D., RAC, Evoke's Chief Medical Officer, opined that the two Phase 2 diabetic gastroparesis studies show effectiveness as well as tolerability of Evoke's patented formulation of metoclopramide when given as nasal spray.

  

Carlson added that the results from the study show that EVK-001 gives meaningful benefits for female patients and that patient gender is predictive of EVK-001's benefits.

   

Shares of the company are up 20% to $5.82.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!